|

Bulevirtide Clinical Trials

6 actively recruiting trials

▼ -1 trial since June 2026

Also known as: BJT-778, Hepcludex

Pipeline

Phase 2/3: 1

Top Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico3
Research Center of Periodontal-Systemic Interactions1
Mirum Pharmaceuticals, Inc.1
Karolinska University Hospital1

Indications

Liver Disease6
Hepatitis D4
Chronic Hepatitis D2
Periodontitis1
Hepatitis B, Chronic1

Other6 trials

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.